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Available online 13 May 2016X-linkedhypophosphatemia (XLH) is characterized by lower extremity deformities that lead to bone and/or joint
pain that result from decreased renal tubular reabsorption leading to hypophosphatemia caused by elevated
levels of ﬁbroblast growth factor 23 (FGF23).
Objective: Validate the use of SF-36v2 Health Survey (SF-36v2) and theWestern Ontario andMcMaster Osteoar-
thritis Index (WOMAC) to measure previously unstudied health-related quality of life (HRQoL) in XLH patients
and determine the change in HRQoL before and after treatment with KRN23, a human monoclonal anti-FGF23
antibody.
Methods: Twenty-eight adult outpatients with XLH received up to four doses of KRN23 administered subcutane-
ously every 28 days. General HRQoL was measured with the SF-36v2 and condition-related HRQoL with the
WOMAC at baseline and study endpoint as a secondary outcome of a Phase 1/2, open-label, multicenter, dose-es-
calation trial.
Results: Testing for scale discriminant validity and convergent-divergent validity supported the use of these
scales in the assessment ofHRQoL inXLH. Both instruments indicated impairment of physical function at baseline
with all mean scores showing a trend to improved health at study endpoint compared to baseline. When
corrected for multiple comparisons, the score for Role Limitations due to physical health on the SF-36v2 which
measures the patient's perception of their own chronic functional impairments due to poor physical health
remained signiﬁcantly improved (P b 0.05), increasing to the mean score of US adults. For theWOMAC, Physical
Functioning and Stiffness scores were signiﬁcantly improved (P b 0.05).
Conclusion: KRN23 administration was associated with signiﬁcantly improved patient perception of their Physi-
cal Functioning and Stiffness due to their disease. This study demonstrates that the SF-36v2 and WOMAC are
valid tools for assessing HRQoL in XLH.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Rickets1. Introduction
X-linked hypophosphatemia (XLH; MIM307800) is a dominant he-
reditary bone disorder resulting from PHEXmutations and characterizedL, health-related quality of life;
ritis Index; MIC, Minimally
ustonMethodist Hospital, 6550
. Ruppe).
. This is an open access article underby elevated levels of ﬁbroblast growth factor 23 (FGF23) leading to a
dual defect in phosphate metabolism with consequent renal phosphate
wasting and impaired renal production of 1,25-dihydroxyvitamin D
[1,25(OH)2D] (Imel & Econs, 2005; Liu & Quarles, 2007; Carpenter et al.,
2011; Lee & Imel, 2013). It is the most common form of heritable rickets,
usually presenting with bowing deformities of the legs in childhood
(Holm et al., 2003). Adults suffer from bone pain and osteomalacia, in-
creased risk of skeletal insufﬁciency fractures, joint abnormalities and
pain, enthesopathy, osteoarthritis, and dental abscesses (Reid et al.,
1989; Tenenhouse & Econs, 2013). Formal assessments of how thisthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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ly reported. It is also not knownwhether treatment inﬂuences quality of
life.
The main therapeutic option, oral calcitriol plus phosphate supple-
ments, offers limited efﬁcacy, is inconvenient to administer, and re-
quires regular monitoring for potential toxicities (Carpenter et al.,
2011; Costa et al., 1981). KRN23 is a recombinant human IgG1monoclo-
nal antibody directed at FGF23. In a recent Phase 1 and Phase 1/2, dose-
escalation study of repeated subcutaneous doses of KRN23 in adults
with XLH, we showed that KRN23 effectively increased the ratio of
renal tubular maximum reabsorption of phosphate to glomerular ﬁltra-
tion rate (TmP/GFR), and serum inorganic phosphorus (Pi) and
1.25(OH)2D concentrations (Carpenter et al., 2014; Imel et al., 2015).
As a secondary objective of the dose escalation study, we sought to as-
sess the psychometric validity of formal health-related quality of life
(HRQoL) testing utilizing two well-established Patient Reported Out-
come (PRO) instruments: general HRQoL was measured with the Med-
ical Outcomes Study Short Form Health Survey version 2 (SF-36v2)
(Maruish, 2011) and condition-related HRQoL with theWestern Ontar-
io and McMaster Osteoarthritis Index (WOMAC) (Bellamy et al., 1988).
In addition, we also sought to evaluate the effects of KRN23 on HRQoL.
2. Methods
2.1. Overall study design
The primary Phase 1/2 studywas an open-label, dose-escalation trial
of KRN23 in adults age ≥ 18 years with a documented clinical diagnosis
of XLH conducted at six study centers. The primary results of this study
have been previously publishedwith the full methods foundwithin that
publication (Imel et al., 2015). Brieﬂy, inclusion criteria were: intact
serum FGF23 level N 30 pg/ml, TmP/GFR b2.0 mg/dl, estimated glomer-
ular ﬁltration rate ≥ 60 ml/min, and serum calcium b10.8 mg/dl. Exclu-
sion criteria included pregnancy or lactation, major surgery, and receipt
of live vaccine ormonoclonal antibody productswithin 3months before
screening. Vitamin D (and its analogues), calcium supplements, phos-
phate supplements and aluminum hydroxide were not permitted with-
in 10 days before screening nor throughout the study. The screening
occurred within 30 days prior to baseline dosing day (Day 0). Patients
received KRN23 0.05 mg/kg subcutaneously at baseline (Day 0) follow-
ed by step-wise dose escalation (0.1 to 0.3 to 0.6mg/kg subcutaneously)
every 4 weeks based on serum Pi levels for a total of four doses.
The clinical study was conducted according to the principles of the
Declaration of Helsinki and with Institutional Review Board approval
at each study center. Written informed consent was obtained from the
participants prior to study inclusion. The studywas conducted between
31 October 2011 and 10 April 2013, and was registered at ClinicalTrials.
gov (#NCT01340482).
2.2. PRO measures
SF-36v2 (Maruish, 2011) and WOMAC (Bellamy et al., 1988;
Bellamy, 2009) were completed by the patients on the day of initial
KRN23 dosing (baseline, Day 0) and at study endpoint (Day 120)
which occurred 36 days after the last dose of KRN23. The 36-question
self-reported SF-36v2 measures eight concepts to evaluate general
HRQoL: Physical Functioning, Role Limitations due to Physical Health,
Bodily Pain, General Health Perceptions, Vitality, Social Functioning,
Role Limitations due to Emotional Problems, and Mental Health. The
Role Limitations scales are construct-based measurements that are
meant to measure more abstract properties. These measures evaluate
the patient's perception of their own chronic functional limitations
due either to poor physical health (Role Limitations due to physical
health) or poor emotional health (Role Limitations due to emotional
health). Norm-based standardized scores are calculated, with scores
below 50 being below the mean for the US population. The eight scalesare then used to compute Physical Component Summary and Mental
Component Summary scores in the same manner as the individual do-
mains to produce standardized scores relative to the general population.
The SF-36v2 iswidely accepted as a validmeasure of disease burden and
has been frequently applied across multiple diseases.
The 24-question self-reported WOMAC was originally designed to
evaluate the condition of the knee, hip, and other joints in patients
with osteoarthritis using three scales: Pain, Stiffness, and Physical Func-
tioning. This study used WOMAC version LK3.1 (Bellamy, 2004) in
which responses to all questions are measured on a 5-point Likert
scale: none (0), mild (1), moderate (2), severe (3) and extreme (4).
Scoring is a simple sum, so Pain scores range from 0 to 20, Stiffness
from 0 to 8, and Physical Functioning from 0 to 68, with higher numbers
indicating worse condition. Scores are normalized to a 0–100 metric
scale for Pain Scores (20 points is 100%), Stiffness (8 points is 100%)
and Physical functioning (68 points is 100%), representing the percent
of the maximum score. Unlike SF-36v2 scores, WOMAC scores are not
norm-based, so they cannot be interpreted directly as a difference
from a population mean. However, mean WOMAC scores from a large
population-based sample of healthy adults have been published
(Bellamy et al., 2011) giving benchmark values for comparison. These
are as follows (mean ± SD): Pain 14.1 ± 19.7, Stiffness 20.1 ± 23.6
and Physical Functioning 15.4 ± 20.2.
2.3. PRO analyses
The aims of the PRO analyseswere to describe baseline quality of life
in XLH, interpret changes in PRO scales over time, and validate PRO
analyses implementation in XLH patients. As described below, disease
burdenwas assessed by comparing the scores to those of a cohort of pa-
tients with a disease having several similarities to XLH (osteoarthritis)
while validation analysis was performed by comparing the scores to
those of a cohort of patients affected with a disease having few similar-
ities (asthma). Both PRO instruments have established algorithms for
estimating scores with missing data and were used in these analyses.
All statistical analyses were performed using SAS version 9.2 (SAS Insti-
tute Inc., Cary, NC).
2.4. Descriptive and interpretative analyses
Patient demographics and their response frequencies to all individu-
al PRO questions were analyzed descriptively. The paired t-test statisti-
cal analysis was then applied to determine whether there were any
signiﬁcant changes in mean PRO scales with treatment.
Signiﬁcance was set at P b 0.05. An adjustment for multiplicity was
made to control the family-wise error rate below a given α of 0.05. To
adjust for multiplicity, a parallel gatekeeping approach was applied
using Hommel's adjustment for the non-primary hypotheses
(Hommel, 1988). The inclusion of PROs as secondary endpoints was ex-
ploratory. For this reason, both the standard P-values of tests (labeled P)
aswell as themultiplicity-adjusted P-values (labeled Pm) are presented.
Interpretative disease burden analyses were then conducted for SF-
36v2 results for the XLH population compared to two age- and sex-
matched SF-36v2 comparator datasets (data on ﬁle at Optum/
QualityMetric, Lincoln, RI): the general United States population (N =
4040) and a subsample with osteoarthritis (N= 583), who were unse-
lected with respect to their treatment of osteoarthritis. These samples
were chosen so that disease burden analyses could be conducted for
XLH relative to the population norm and to a known clinical disease
that has some symptoms in common with XLH. The change in values
was compared to the Minimally Important Change (MIC). MIC is the
smallest change over time in an individual patient's score that repre-
sents a clinically signiﬁcant change in their health status. Using a distri-
butional approach with a U.S. general population sample, MIC scores
have been established for the SF-36v2 as: Physical Functioning, 3.5;
Role Limitations due to Physical Health, 3.2; Bodily Pain, 4.5; General
Table 1
Change in mean PRO scores and signiﬁcance over time in the completer population (N=
26).
PRO
instrument
Scale
Mean ± SD score Change
in mean*
Statistics
Baseline Endpoint P Pm
SF-36v2
PF 41.1 ± 10.2 42.8 ± 10.4 1.77 0.1264 1.0000
RP 45.1 ± 9.9 50.6 ± 7.8 5.53 0.0012 0.0198
BP 42.2 ± 9.1 45.5 ± 9.1 3.27 0.0287 0.2209
GH 48.1 ± 9.5 48.3 ± 8.5 0.17 0.8820 1.0000
VT 46.5 ± 10.9 48.9 ± 9.6 2.40 0.1030 1.0000
SF 48.1 ± 10.3 50.4 ± 8.8 2.31 0.1554 1.0000
RE 48.9 ± 9.6 51.8 ± 8.8 2.81 0.0718 1.0000
MH 51.3 ± 8.2 53.7 ± 9.8 2.42 0.0509 0.8489
PCS 41.4 ± 10.3 44.1 ± 9.4 2.75 0.0426 0.5328
MCS 52.3 ± 10.3 54.5 ± 10.2 2.17 0.1542 1.0000
WOMAC
Pain 30.0 ± 18.8 26.2 ± 19.7 −3.8 0.2182 1.0000
Physical
Functioning
29.3 ± 21.3 23.9 ± 17.9 −5.4 0.0077 0.0968
Stiffness 42.8 ± 20.9 35.6 ± 19.5 −7.2 0.0405 0.5064
BP, Bodily Pain; GH, General Health Perceptions;MH,MentalHealth;MCS,Mental Compo-
nent Summary; P, standard P-value; Pm, multiplicity-adjusted P-value; PCS, Physical Com-
ponent Summary; PF, Physical Functioning; PRO, Patient Reported Outcome; RE, Role
Limitations due to Emotional Problems; RP, Role of Limitations due to Physical Health;
SF, Social Functioning; SF-36v2, Medical Outcomes Study Short Form Health Survey, ver-
sion 2; VT, Vitality; WOMAC, Western Ontario and McMaster Osteoarthritis Index.
⁎ Positive change indicates improved health on SF-36v2 scale and negative change in-
dicates improved health on WOMAC scale.
160 M.D. Ruppe et al. / Bone Reports 5 (2016) 158–162Health Perceptions, 5.7; Vitality, 5.5; Social Functioning, 5.0; Role Limi-
tations due to Emotional Health, 3.8; Mental Health, 5.5; Physical Com-
ponent Score, 3.1; and Mental Component Score, 3.8 (Maruish, 2011).
The User's Manual for the WOMAC lists MICs as 9.7 for Pain, 10.0 for
Stiffness, and 9.3 for Physical Functioning (Bellamy, 2009).
2.5. Validation analyses
Scale discriminant validity was determined by disease burden anal-
ysis for SF-36v2 results at baseline and endpoint compared to a repre-
sentative reference sample (patients with asthma), for which an age-
and sex-matched SF-36v2 comparator dataset is available and presents
a medical condition that is clinically different from XLH. Convergent-di-
vergent validity was assessed by calculating correlation coefﬁcients be-
tween conceptually-related pairs from the SF-36v2 and WOMAC scales
at baseline and endpoint.
3. Results
3.1. Patient demographic and baseline characteristics
PRO assessments were undertaken at baseline in the 28 patients
who were enrolled in the study and in the 26 patients who completed
the study. Two patients withdrew from the study due to a pre-existing
condition and injection site urticaria, respectively. For the sample com-
pleting the study (N=26), mean age was 41.9 (SD 14.1; range, 19–66),
17 (65.4%) were female, all but one was Caucasian (25, 96.2%), and
mean bodyweight was 77.3 kg (SD 19.9, range 46.4 kg–121.9 kg)
The median duration between stopping therapy with oral calcitriol
plus phosphate and initial KRN23 dosing was 44 days (range, 25 days
to 50.4 years).
At baseline, median intact FGF23 measured using a validated ELISA
method was 95 pg/ml (range, 36–3520). Mean serum Pi was 1.9 mg/dl
(SD0.3) andTmP/GFRwas 1.6mg/dl (SD0.4),whichwere below thenor-
mal reference ranges (2.5–4.3 mg/dl and 2.5–4.2 mg/dl, respectively).
Mean 1,25(OH)2D, 25-hydroxyvitamin D, serum calcium, parathyroid
hormone, bone alkalinephosphatase, 24-hour urine calcium, 24-hour cre-
atinine and fasting 2-hour urine calcium/creatinine ratiowerewithinnor-
mal ranges.
3.2. Dose and exposure
All participants received the initial KRN23dose of 0.05mg/kg. For dose
2, 26 (96.3%) escalated to 0.1mg/kg, andone remained at 0.05mg/kg, and
one withdrew. For dose 3, 25 (92.6%) escalated to 0.3 mg/kg, one contin-
ued at 0.05 mg/kg and one at 0.1 mg/kg. For dose 4, 16 (61.5%) escalated
to 0.6 mg/kg, eight continued at 0.3 mg/kg, one increased from 0.05 to
0.1 mg/kg, one from 0.1 to 0.3 mg/kg, and one withdrew. No patient re-
quired dose delay or reduction.
3.3. Responses to PRO questions
For the SF-36v2, where lower scores indicate worse functioning, the
subjects rated all physical scales at baseline below those of the general
population. Only mental health and mental composite score were
higher than themean for the U.S. population (Table 1).When evaluated
for signiﬁcance, mean Bodily Pain (P b 0.0001), Physical Functioning
(P b 0.0001), Role Limitations due to Physical Health (P = 0.0054;
Pm = 0.0162), and Physical Component Score (P b 0.0001) scores
were far below the general U.S. population norm, while all other scales
did not show a statistically signiﬁcant difference. Likewise on the
WOMAC, where higher scores indicate worse perceived functioning,
all scales were above the established norms (Table 1).
At endpoint, mean scores for all SF-36v2 scales increased and those
for WOMAC decreased (Table 1) from baseline. At endpoint, the mean
Mental Health (P = 0.03) and Mental Component Score (P = 0.009)scales became signiﬁcantly higher than the U.S. norm; mean Role Limi-
tations due to Physical Health (P= 0.95; Pm = 0.95) became normal;
mean Physical Component Score (P= 0.0004), Bodily Pain (P= 0.01),
and Physical Functioning (P = 0.0001) remained signiﬁcantly lower
than the norm; and the other scales (Role Limitations due to Emotional
Health, Social Functioning, Vitality and General Health) remained nor-
mal. Only Role Limitations due to Physical Health from the SF-36v2
retained signiﬁcance (Pm = 0.02) after correction for multiplicity
(Table 1). Additionally, Role Limitations due to Physical Health crossed
the established threshold for MIC, which represents the smallest incre-
ment that represents a clinically signiﬁcant change in health status
3.4. 3.3 disease burden analyses
At baseline, disease burden for the XLH patients was different from
patients with osteoarthritis (Fig. 1). General Health (P= 0.009), Bodily
Pain (P = 0.03), and Social Functioning (P = 0.01) scores for XLH pa-
tients were signiﬁcantly higher than those of the osteoarthritis sample
at baseline, indicating better health in the XLH group, and all other
scores were no different. At endpoint, all mean SF-23v2 scale scores
for XLH patients except Physical Functioning and Role Limitations due
to Emotional Healthwere improved relative to the baseline osteoarthri-
tis scores: Role Limitations due to Physical Health (P b 0.0001;
Pm b 0.0001), Bodily Pain (P=0.0003), General Health (P=0.004), Vi-
tality (P=0.006), Social Functioning (P=0.0002), Mental Health (P=
0.008), Physical Component Score (P=0.007), and Mental Component
Score (P= 0.01).
3.5. Validation analyses
For scale discriminant validity of the use of SF-36v2, the XLH scores
were compared to those of a populationwith asthma (N=343, data on
ﬁle at Optum/QualityMetric). Fig. 2 shows the difference betweenmean
SF-36v2 scale scores for XLH patients and the means for asthma pa-
tients. For the SF-36v2, the subjects rated all scales at or above those
of the asthma patients at baseline.
Convergent-divergent validity was assessed from correlations be-
tween SF-36v2 and WOMAC scales for all PRO measurements at base-
line (N = 28) and endpoint (N = 26). The correlation coefﬁcient
Fig. 1.Mean scale score difference between XLH patients and an age- and sex-matched
osteoarthritis sample at baseline and endpoint (Day 120) on SF-36v2 scales. Horizontal
dotted line shows threshold for statistically signiﬁcant difference (P b 0.05, better
relative health above upper horizontal dotted line and worse relative health below
lower horizontal dotted line) or no signiﬁcant difference (P N 0.05, between the two
horizontal dotted lines) of scale scores between the trial population and osteoarthritis
patients. Abbreviations: BP, Bodily Pain; GH, General Health Perceptions; MH, Mental
Health; MCS, Mental Component Summary; PCS, Physical Component Summary; PF,
Physical Functioning; RE, Role Limitations due to Emotional Problems; RP, role of
limitations due to Physical Health; SF, Social Functioning; VT, Vitality.
Fig. 2.Mean scale score difference between XLH patients and an age- and sex-matched
asthma population at baseline and endpoint (Day 120) on SF-36v2 scales. Horizontal
dotted lines show thresholds for statistically signiﬁcant difference (P b 0.05 with better
relative health above upper horizontal line and worse relative health below lower
horizontal dotted line) or no signiﬁcant difference (P N 0.05, between the two dotted
horizontal lines) of scale scores between the trial population and asthma patients.
Abbreviations: BP, Bodily Pain; GH, general health perceptions; MH, Mental Health;
MCS, Mental Component Summary; PCS, Physical Component Summary; PF, Physical
Functioning; RE, Role Limitations due to Emotional Problems; RP, role of limitations due
to Physical Health; SF, Social Functioning, VT, Vitality.
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Pain (−0.79) and Physical Functioning from the SF-36v2 and Physical
Functioning from the WOMAC (−0.81) were highly correlated (the
negative sign reﬂects the opposing direction of the two PRO instrument
scales). All other correlations were smaller, although some were nearly
as high, e.g., Bodily Pain and Physical Functioning (−0.76), Physical
Functioning and Pain (−0.73). Other less conceptually related scales,
such as Mental Health and Stiffness, were far less correlated (−0.07).
4. Discussion
It has long been recognized that patients with XLH report muscle
weakness and bone pain (Reid et al., 1989; Nunnally, 1978; Sullivan et
al., 1992; Bergwitz et al., 2006; Schott & Wills, 1976). It has been as-
sumed that patients with XLH have an impaired quality of life due to
bone pain, fractures, enthesopathies, osteoarthritis, joint pain and den-
tal abscesses; however, HRQoL has not been systematically evaluated in
this disease. With an improving understanding of the disease patho-
physiology and particularly with new treatments under development,
it is important to establish methods to assess HRQoL in XLH. In this
study, the use of the SF-36v2 andWOMAC as instruments for PRO anal-
ysis in adults with XLH was validated before and after the intervention
with KRN23, a drug developed to block FGF23 action.
Both PRO instruments (SF-36v2 and WOMAC) appear to be appro-
priate and validmeasures of HRQoL in XLHpatients. SF-36v2was select-
ed as a candidate PRO instrument as it has been extensively used to
evaluate general HRQoL across a broad range of diseases and clinical
conditions. WOMAC, however, was speciﬁcally developed to measure
HRQoL in patients with osteoarthritis (Bellamy, 2002), but has also
been used in other painful musculoskeletal disorders such as back
pain, rheumatoid arthritis, and ﬁbromyalgia (Wolfe, 1999). Given the
major symptomoverlap between osteoarthritis andXLH, it was hypoth-
esized that WOMAC would also be applicable as a PRO instrument in
adults with XLH for HRQoL assessment.Using these instruments, we demonstrate the signiﬁcant burden of
XLH on HRQoL. Compared to the general US population, the XLH trial
patients showed lower physical HRQoL with deﬁcits in baseline Bodily
Pain, Physical Functioning, Role Limitations due to Physical Health,
and Physical Component Score scales, and normal to high levels ofmen-
tal HRQoL (Mental Health andMental Component Score) of the SF-36v2
instrument.
Additionally, using the two PRO instruments (SF-36v2 and
WOMAC), we show HRQoL improved in patients with XLH after four
months of KRN23 treatment. At the end of the study, the Role Limita-
tions due to Physical Health deﬁcitwas eliminated; Physical Component
Score, Bodily Pain, and Physical Functioning deﬁcits were lessened but
remained below the US norm; Mental Health and Mental Component
Score became higher than the norm; and other scales showed increased
scores but were not different from the norm. In particular the area with
themost signiﬁcant change, the Role Limitations due to Physical Health
concept scale represents the patient's perception of their own chronic
functional physical limitations due to poor health with this scale felt
to be one of the best measures to detect the impact of interventions
that affect physical health (Ware &Kosinski, 2001). Importantly, the im-
provement in Role Limitations due to Physical Health was greater than
the minimally signiﬁcant change for this parameter following the
therapy.
The validation analysis, using an asthma population for the compar-
ator group, showed expected associations with the pattern of change
observed in our comparison to the general US population. In that the
asthma population is a subset of the general U.S. population (with at
least one medical condition), this overall pattern is expected, and sup-
ports the discriminant validity of SF-36v2 used in an XLH population.
It has recently been demonstrated that lower limb muscle density,
and peak force and power are signiﬁcantly reduced in XLH patients
(Veilleux et al., 2012; Veilleux et al., 2013), with depletion of ATP
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1999) being proposed as mechanism for muscle weakness associated
with chronic hypophosphatemia. It could be speculated that increased
muscle strength as noted by Role Limitations due to Physical Health
(Pm= 0.0198) might contribute to the improved HRQoL observed dur-
ing the administration of KRN23 among XLH patients in the current
study.
The major strength of our study is that to our knowledge, this is the
ﬁrst time HRQoL has been formally evaluated in XLH patients. In addi-
tion, we validated two readily available instruments that can be used
by others for evaluation of subjects with XLH. There are some limita-
tions to our study. One consideration when interpreting these HRQoL
results is that the patients only received four KRN23 doses. Further-
more, therapy was titrated from a relatively low starting dose
(0.05 mg/kg) to a maximum of 0.6 mg/kg. Thus, potentially sub-thera-
peutic doses were administered for the initial portions of a relatively
short overall study duration which may have affected the ability to de-
tect signiﬁcant improvement for domains apart from Role Limitations
due to Physical Health. Furthermore, the results should also be
interpreted cautiously due to small sample size (N = 26) and the
open-label study design.
5. Conclusion
In conclusion, SF-36v2 and WOMAC were validated for use in XLH.
The instruments showdecreasedHRQoL scores in XLH patients, and sig-
niﬁcant improvement in patient perception of their Physical Function-
ing following four doses of KRN23 given every 28 days. These PRO
instruments (SF-36v2 andWOMAC) should provide a valuable addition
to clinical, biochemical, and radiologic criteria in evaluating new treat-
ment options in adults with XLH.
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